A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of TPOXX When Administered Orally for 28 Days in Adult Subjects
Latest Information Update: 26 Aug 2024
At a glance
- Drugs Tecovirimat (Primary)
- Indications Smallpox
- Focus Adverse reactions; Registrational
- Sponsors SIGA Technologies
- 17 Jul 2023 Status changed from recruiting to completed.
- 06 Oct 2022 Planned primary completion date changed from 31 Dec 2022 to 31 Jan 2023.
- 23 May 2022 Status changed from not yet recruiting to recruiting.